194 related articles for article (PubMed ID: 32048105)
21. Molecular analysis of PALB2-associated breast cancers.
Lee JEA; Li N; Rowley SM; Cheasley D; Zethoven M; McInerny S; Gorringe KL; James PA; Campbell IG
J Pathol; 2018 May; 245(1):53-60. PubMed ID: 29431189
[TBL] [Abstract][Full Text] [Related]
22. The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.
Nepomuceno TC; De Gregoriis G; de Oliveira FMB; Suarez-Kurtz G; Monteiro AN; Carvalho MA
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28858227
[TBL] [Abstract][Full Text] [Related]
23. A synonymous germline variant PALB2 c.18G>T (p.Gly6=) disrupts normal splicing in a family with pancreatic and breast cancers.
Yang C; Ceyhan-Birsoy O; Mandelker D; Jairam S; Catchings A; O'Reilly EM; Walsh MF; Zhang L
Breast Cancer Res Treat; 2019 Jan; 173(1):79-86. PubMed ID: 30255452
[TBL] [Abstract][Full Text] [Related]
24. Evolutionary Origin of Human
Chian JS; Li J; Wang SM
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511102
[No Abstract] [Full Text] [Related]
25. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.
Xia B; Sheng Q; Nakanishi K; Ohashi A; Wu J; Christ N; Liu X; Jasin M; Couch FJ; Livingston DM
Mol Cell; 2006 Jun; 22(6):719-729. PubMed ID: 16793542
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
[TBL] [Abstract][Full Text] [Related]
27. Characterisation of protein-truncating and missense variants in
Ng PS; Boonen RA; Wijaya E; Chong CE; Sharma M; Knaup S; Mariapun S; Ho WK; Lim J; Yoon SY; Mohd Taib NA; See MH; Li J; Lim SH; Tan EY; Tan BK; Tan SM; Tan VK; van Dam RM; Rahmat K; Yip CH; Carvalho S; Luccarini C; Baynes C; Dunning AM; Antoniou A; van Attikum H; Easton DF; Hartman M; Teo SH
J Med Genet; 2022 May; 59(5):481-491. PubMed ID: 33811135
[TBL] [Abstract][Full Text] [Related]
28. PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk.
Vagena A; Papamentzelopoulou M; Kalfakakou D; Kollia P; Papadimitriou C; Psyrri A; Apostolou P; Fountzilas G; Konstantopoulou I; Yannoukakos D; Fostira F
J Hum Genet; 2019 Aug; 64(8):767-773. PubMed ID: 31089269
[TBL] [Abstract][Full Text] [Related]
29. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
30. Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients.
Obermeier K; Sachsenweger J; Friedl TW; Pospiech H; Winqvist R; Wiesmüller L
Oncogene; 2016 Jul; 35(29):3796-806. PubMed ID: 26640152
[TBL] [Abstract][Full Text] [Related]
31. A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
Velázquez C; Esteban-Cardeñosa EM; Lastra E; Abella LE; de la Cruz V; Lobatón CD; Durán M; Infante M
Breast; 2019 Feb; 43():91-96. PubMed ID: 30521987
[TBL] [Abstract][Full Text] [Related]
32. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
Breast Cancer Res Treat; 2020 Feb; 179(3):605-614. PubMed ID: 31768816
[TBL] [Abstract][Full Text] [Related]
33. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Alter BP; Best AF
Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
[TBL] [Abstract][Full Text] [Related]
34. Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
Cerretini R; Mercado G; Morganstein J; Schiaffi J; Reynoso M; Montoya D; Valdéz R; Narod SA; Akbari MR
Breast Cancer Res Treat; 2019 Dec; 178(3):629-636. PubMed ID: 31446535
[TBL] [Abstract][Full Text] [Related]
35. Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report.
Lopez-Perolio I; Leman R; Behar R; Lattimore V; Pearson JF; Castéra L; Martins A; Vaur D; Goardon N; Davy G; Garre P; García-Barberán V; Llovet P; Pérez-Segura P; Díaz-Rubio E; Caldés T; Hruska KS; Hsuan V; Wu S; Pesaran T; Karam R; Vallon-Christersson J; Borg A; ; Valenzuela-Palomo A; Velasco EA; Southey M; Vreeswijk MPG; Devilee P; Kvist A; Spurdle AB; Walker LC; Krieger S; de la Hoya M
J Med Genet; 2019 Jul; 56(7):453-460. PubMed ID: 30890586
[TBL] [Abstract][Full Text] [Related]
36. Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines.
Wark L; Novak D; Sabbaghian N; Amrein L; Jangamreddy JR; Cheang M; Pouchet C; Aloyz R; Foulkes WD; Mai S; Tischkowitz M
Genes Chromosomes Cancer; 2013 May; 52(5):480-94. PubMed ID: 23341105
[TBL] [Abstract][Full Text] [Related]
37. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
38. Genetic analysis of PALB2 gene WD40 domain in canine mammary tumour patients.
Çıldır ÖŞ; Özmen Ö; Kul S; Rişvanlı A; Özalp G; Sabuncu A; Kul O
Vet Med Sci; 2024 May; 10(3):e1366. PubMed ID: 38527110
[TBL] [Abstract][Full Text] [Related]
39. Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
Deng M; Chen HH; Zhu X; Luo M; Zhang K; Xu CJ; Hu KM; Cheng P; Zhou JJ; Zheng S; Chen YD
Int J Cancer; 2019 Sep; 145(6):1517-1528. PubMed ID: 30720863
[TBL] [Abstract][Full Text] [Related]
40. Cancer Risks Associated With Germline
Yang X; Leslie G; Doroszuk A; Schneider S; Allen J; Decker B; Dunning AM; Redman J; Scarth J; Plaskocinska I; Luccarini C; Shah M; Pooley K; Dorling L; Lee A; Adank MA; Adlard J; Aittomäki K; Andrulis IL; Ang P; Barwell J; Bernstein JL; Bobolis K; Borg Å; Blomqvist C; Claes KBM; Concannon P; Cuggia A; Culver JO; Damiola F; de Pauw A; Diez O; Dolinsky JS; Domchek SM; Engel C; Evans DG; Fostira F; Garber J; Golmard L; Goode EL; Gruber SB; Hahnen E; Hake C; Heikkinen T; Hurley JE; Janavicius R; Kleibl Z; Kleiblova P; Konstantopoulou I; Kvist A; Laduca H; Lee ASG; Lesueur F; Maher ER; Mannermaa A; Manoukian S; McFarland R; McKinnon W; Meindl A; Metcalfe K; Mohd Taib NA; Moilanen J; Nathanson KL; Neuhausen S; Ng PS; Nguyen-Dumont T; Nielsen SM; Obermair F; Offit K; Olopade OI; Ottini L; Penkert J; Pylkäs K; Radice P; Ramus SJ; Rudaitis V; Side L; Silva-Smith R; Silvestri V; Skytte AB; Slavin T; Soukupova J; Tondini C; Trainer AH; Unzeitig G; Usha L; van Overeem Hansen T; Whitworth J; Wood M; Yip CH; Yoon SY; Yussuf A; Zogopoulos G; Goldgar D; Hopper JL; Chenevix-Trench G; Pharoah P; George SHL; Balmaña J; Houdayer C; James P; El-Haffaf Z; Ehrencrona H; Janatova M; Peterlongo P; Nevanlinna H; Schmutzler R; Teo SH; Robson M; Pal T; Couch F; Weitzel JN; Elliott A; Southey M; Winqvist R; Easton DF; Foulkes WD; Antoniou AC; Tischkowitz M
J Clin Oncol; 2020 Mar; 38(7):674-685. PubMed ID: 31841383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
